PE17299A1 - Derivados de pirimidina biciclica condensada - Google Patents

Derivados de pirimidina biciclica condensada

Info

Publication number
PE17299A1
PE17299A1 PE1997001057A PE00105797A PE17299A1 PE 17299 A1 PE17299 A1 PE 17299A1 PE 1997001057 A PE1997001057 A PE 1997001057A PE 00105797 A PE00105797 A PE 00105797A PE 17299 A1 PE17299 A1 PE 17299A1
Authority
PE
Peru
Prior art keywords
alkyl
optionally substituted
ilo
formula
pirimidine
Prior art date
Application number
PE1997001057A
Other languages
English (en)
Inventor
Lee Daniel Arnold
Mikel Paul Moyer
Susan Beth Sobolov-Jaynes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE17299A1 publication Critical patent/PE17299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: EL ANILLO QUE FORMA "Z" ES PIRROL o PIRIDINA OPCIONALMENTE SUSTITUIDOS; R1 ES H, ALQUILO C1-C6, CO-ALQUILO C1-C6; R2 ES FENILO, 1H-INDAZOL-5-ILO, BENZO[b]TIOFENO-5-ILO, ESTANDO DICHOS GRUPOS OPCIONALMENTE SUSTITUIDOS CON 1 A 3 SUSTITUYENTES R5, o INDOL-5-ILO OPCIONALMENTE SUSTITUIDO; o R1 Y R2 SE UNEN PARA FORMAR UN RADICAL DE FORMULA (Ik), EN DONDE: R3 ES H, COOR9, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO POR HALOGENO, OR9, NR9R10 o COOR9; R4 ES R3, OR9 o NR9 R10; R5 ES HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS; R9 Y R10 SON H o ALQUILO C1-C6; m ES 0-4. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO INHIBIDORES DE LA FAMILIA erbB DE LAS PROTEINAS TIROSIN QUINASAS ONCOGENICAS Y PROTOONCOGENICAS COMO EL FACTOR DE CRECIMIENTO EPIDERMICO (EGFR), ENTRE OTROS, SIENDO UTILES EN EL TRATAMIENTO DE TUMORES MALIGNOS Y BENIGNOS Y OTRAS AFECCIONES HIPERPLASICAS COMO HIPERPLASIA BENIGNA DE LA PIEL, DE LA PROSTATA, ENTRE OTROS
PE1997001057A 1996-11-27 1997-11-20 Derivados de pirimidina biciclica condensada PE17299A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3186296P 1996-11-27 1996-11-27
US4184697P 1997-04-09 1997-04-09

Publications (1)

Publication Number Publication Date
PE17299A1 true PE17299A1 (es) 1999-02-19

Family

ID=26707706

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997001057A PE17299A1 (es) 1996-11-27 1997-11-20 Derivados de pirimidina biciclica condensada

Country Status (24)

Country Link
US (1) US6413971B1 (es)
EP (1) EP0946554A1 (es)
JP (1) JP2000505109A (es)
KR (1) KR20000057228A (es)
CN (1) CN1237177A (es)
AP (1) AP9701146A0 (es)
AR (1) AR010740A1 (es)
AU (1) AU4718997A (es)
BG (1) BG103417A (es)
BR (1) BR9713552A (es)
CA (1) CA2272705C (es)
CO (1) CO4650037A1 (es)
HN (1) HN1997000146A (es)
HR (1) HRP970641A2 (es)
ID (1) ID18958A (es)
IL (1) IL129825A0 (es)
IS (1) IS5041A (es)
MA (1) MA26452A1 (es)
NO (1) NO992524D0 (es)
OA (1) OA11051A (es)
PA (1) PA8442001A1 (es)
PE (1) PE17299A1 (es)
TN (1) TNSN97192A1 (es)
WO (1) WO1998023613A1 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2177925T3 (es) * 1996-01-23 2002-12-16 Novartis Ag Pirrolopirimidinas y procedimientos para su preparacion.
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP2001500890A (ja) 1996-09-25 2001-01-23 ゼネカ リミテッド Ｖｅｇｆのような成長因子の作用を阻害するキノリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
KR100415791B1 (ko) 1998-06-19 2004-01-24 화이자 프로덕츠 인코포레이티드 피롤로[2,3-디]피리미딘 화합물
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
TR200201051T2 (tr) 1999-10-19 2002-09-23 Merck & Co., Inc. Tirosin kinaz inhibitörleri.
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
WO2001042246A2 (en) 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
AU2728201A (en) 1999-12-21 2001-07-03 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1287001B1 (en) 2000-06-06 2004-09-29 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
AU2687702A (en) 2000-10-17 2002-04-29 Merck & Co Inc Orally active salts with tyrosine kinase activity
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
CZ20031125A3 (cs) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Nové sloučeniny
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003037252A2 (en) 2001-10-30 2003-05-08 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20040085151A (ko) 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
JP2005527511A (ja) 2002-03-01 2005-09-15 ファイザー インコーポレイテッド 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
EP1572213A1 (en) 2002-11-26 2005-09-14 Pfizer Products Inc. Method of treatment of transplant rejection
MXPA05006123A (es) * 2002-12-13 2005-09-30 Neurogen Corp Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
BRPI0413876A (pt) 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
EP1678173A2 (en) * 2003-09-09 2006-07-12 Neurogen Corporation 4-heterobicyclylamino-substituted quinazolines and analogues thereof as capsaicin-antagonists
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
WO2005047289A1 (en) * 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
BRPI0418102A (pt) 2003-12-23 2007-04-27 Pfizer derivados de quinolina
WO2005116035A1 (en) 2004-05-27 2005-12-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
CN1993362B (zh) * 2004-06-02 2010-12-15 武田药品工业株式会社 稠合的杂环化合物
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US7541367B2 (en) * 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
KR20080080395A (ko) * 2005-12-21 2008-09-03 아보트 러보러터리즈 항바이러스 화합물
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
RU2467007C2 (ru) * 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
TWI392676B (zh) * 2005-12-21 2013-04-11 Abbott Lab 抗病毒化合物、其製備方法及用途
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
CN101611041A (zh) 2006-12-12 2009-12-23 武田药品工业株式会社 稠合杂环化合物
US8236950B2 (en) * 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2222162B1 (en) * 2007-11-28 2016-11-16 Dana-Farber Cancer Institute, Inc. Small molecule myristate inhibitors of bcr-abl and methods of use
US20090233937A1 (en) 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
RU2493157C2 (ru) 2008-08-20 2013-09-20 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
EP2670244B1 (en) 2011-02-04 2018-04-11 Duquesne University of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP2852595B1 (en) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
NZ702571A (en) * 2012-06-29 2017-02-24 Pfizer 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2900670A1 (en) 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
WO2014048869A1 (en) 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
BR112015011974A8 (pt) * 2012-11-29 2019-10-08 Merck Patent Gmbh derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
PE20170684A1 (es) 2014-08-04 2017-06-15 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR102369405B1 (ko) 2015-06-04 2022-03-02 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
LT3497103T (lt) 2016-08-15 2021-07-26 Pfizer Inc. Piridopirimidinono cdk2/4/6 inhibitoriai
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
JP2023519603A (ja) 2020-03-31 2023-05-11 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU686843B2 (en) * 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
JPH089637A (ja) * 1994-06-20 1996-01-12 Shindengen Electric Mfg Co Ltd Ｆｅｔによる出力スイッチの駆動回路
NZ304859A (en) * 1995-04-03 2000-01-28 Novartis Ag 4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US5804685A (en) * 1995-06-07 1998-09-08 Neurogen Corporation Deazapurine derivatives: a new class of CRF1 specific ligands
JPH08329674A (ja) * 1995-06-02 1996-12-13 Hitachi Ltd 半導体装置
MX9709867A (es) * 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
DE69715241T2 (de) * 1996-11-26 2003-01-02 American Cyanamid Co Biaryl-pyridochinazolinonderivate als antikrebsmittel

Also Published As

Publication number Publication date
US20020045630A1 (en) 2002-04-18
NO992524L (no) 1999-05-26
IS5041A (is) 1999-04-30
MA26452A1 (fr) 2004-12-20
CO4650037A1 (es) 1998-09-03
WO1998023613A1 (en) 1998-06-04
NO992524D0 (no) 1999-05-26
OA11051A (en) 2003-03-07
ID18958A (id) 1998-05-28
BR9713552A (pt) 2000-01-25
CA2272705A1 (en) 1998-06-04
PA8442001A1 (es) 2000-05-24
TNSN97192A1 (fr) 2005-03-15
JP2000505109A (ja) 2000-04-25
HRP970641A2 (en) 1998-10-31
AR010740A1 (es) 2000-07-12
US6413971B1 (en) 2002-07-02
IL129825A0 (en) 2000-02-29
AP9701146A0 (en) 1998-01-31
CA2272705C (en) 2003-03-18
BG103417A (en) 2000-06-30
HN1997000146A (es) 1998-02-26
CN1237177A (zh) 1999-12-01
EP0946554A1 (en) 1999-10-06
AU4718997A (en) 1998-06-22
KR20000057228A (ko) 2000-09-15

Similar Documents

Publication Publication Date Title
PE17299A1 (es) Derivados de pirimidina biciclica condensada
PT870768E (pt) Derivados azaindole-etilamina como agentes de ligacao nicotinicos aos receptores de acetilcolina
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
DE69520282T2 (de) Pyrrolo[2,3-d]pyrimidinderivate und ihre verwendung
AR004517A1 (es) Compuestos de imidazolin-2-4 diona sustituida, procedimiento de preparacion de dichos compuestos, y aplicacion para el uso de estos compuestos
AR245700A1 (es) Nuevos derivados de la 2-anilino-pirimidina como agentes antiparasitarios.
ES2161290T3 (es) Derivados de quinazolina.
FI896236A0 (fi) Kinoxalinfoereningar och framstaellning och anvaendning av dem.
MX9303213A (es) Derivados de acido ditiofosforico como aditivos lubricantes.
ES2115058T3 (es) Derivados basicos de acido glutamico y acido aspartico como antagonistas de la gastrina o colecistoquinina.
ES2052521T3 (es) Derivados de aminoimidazoquinolina.
PE69398A1 (es) Antagonistas de receptor de benzoxazinona dopamina d4
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
MX9304399A (es) Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
PT81004B (pt) Processo para a preparacao de oxindoles trigiclicos uteis como agentes anti-inflamatorios
MY101261A (en) New 4-pyridone derivatives, method of their production and their pharmaceutical compositions.
DE69629341D1 (de) Pyrrolocarbazolderivate
DE69514532T2 (de) Indol-2,3-dione-3-oximderivate, ihre herstellung und verwendung
FI845102L (fi) Imidazo/1,2-c/pyrimidiner.
DE69529499D1 (de) Stereoselektives Verfahren zur Herstellung von Dihydro-2,3-benzodiazepin-Derivaten
ES2187783T3 (es) Derivados de indolina utiles como antagonistas del receptor 5-ht-2c.
ES2062088T3 (es) Agente para la proteccion de plantas contra enfermedades.
GB1473704A (en) styrylbenzoxazoles and their use as optical brighteners
ES2038218T3 (es) Un procedimiento para preparar nuevos derivados de 2-alquilsulfinil-4(3h)-quinazolinona.

Legal Events

Date Code Title Description
FC Refusal